TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of COPD confirmed by post-bronchodilator spirometry demonstrating (forced expiratory volume at 1 second(FEV1)/forced vital capacity (FVC) \< 0.70 and forced expiratory volume at 1 second (FEV1) in GOLD 2 or 3 stage (30%≤ (forced expiratory volume at 1 second \[FEV1\] \< 80%)~* Willing and able to give informed consent and adhere to visit/protocol schedules~* Women of childbearing potential must have a negative urine pregnancy test~Exclusion Criteria:~* Upper respiratory tract infection within 6 weeks~* Chronic systemic corticosteroid use \> 10 mg/day of prednisone~  * Chronic oxygen use (intermittent or continuous)~ * Previous lung resection surgery or decortication~ * Previous history of pneumothorax~ * Evidence of interstitial, occupational or chronic infectious lung disease by imaging studies~ * History of exposure to occupational or environmental hazards that are known to cause lung diseases~ * For women of child bearing potential, positive pregnancy test~ * Major chronic illnesses which in the judgement of the study physician would interfere with participation in the study~ * Patients who are not willing to withhold COPD inhalers for the run-in period.~    * MRI is contraindicated based on responses to MRI screening questionnaire~   * Subject is pregnant or lactating~   * Respiratory illness of a bacterial or viral etiology within 30 days of MRI~   * Subject has any form of known cardiac arrhythmia~   * Subject does not fit into 129Xe vest coil used for MRI~   * Subject cannot hold his/her breath for 15 seconds~   * Subject deemed unlikely to be able to comply with instructions during imaging

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adding Phosphorus to Osteoporosis Drug Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bone mineral density (BMD) T-score less than -1.0~* One or more vertebral fractures~* Serum creatinine less than 1.3 mg/dL~* Serum phosphorus less than 3.6 mg/dL~* Daily phosphorus intake below NHANES-III median~* Body mass index (BMI) less than 30 kg/m2~Exclusion Criteria:~* Paget's disease or history of osteosarcoma~* Systemic corticosteroid therapy~* Hyperparathyroidism~* Recent history of kidney stone~* Anticonvulsant therapy known to alter vitamin D metabolism~* Radiation therapy to bone

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Calcium Phosphate Treatment Group (Type: ACTIVE_COMPARATOR): Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
- Calcium Carbonate Treatment Group (Type: ACTIVE_COMPARATOR): Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotic in Dry Eye Syndromes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* 18\<age\<60~* BCVA (Best Corrected Visual Acuity) \>=9/10~* At least 2 subjective complaints compatible with dry eye~* TBUT (Tear Break-Up Time) \<= 10 sec, Schirmer's test \<= 10mm~* Signed informed consent, voluntary adherence to treatment~Exclusion Criteria:~* Pregnancy/breastfeeding~* Conjunctivitis~* Thyroid disease~* Diabetes~* Rheumatologic diseases including Sjogren's syndrome~* Neurologic conditions, including stroke, Bell's palsy, Parkinson's, trigeminal nerve problem~* Refractive surgery (LASIK or PRK)~* Other Eye Surgeries~* HSV Keratitis~* Medication/supplement use, including psychiatric medicines, OTC cold medicines, anti-histamines, beta-blockers, pain relievers, sleeping pills, diuretics, Hormones replacement, and oral contraceptives~* Chemical splashes / injuries to the eyes~* Contact lens use~* Environmental (dusty, windy, hot/dry)~* Any treatment for dry eye in previous 4 weeks (including lubricants, steroids, cyclosporine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ophthalmic probiotic (Type: EXPERIMENTAL): 1 active drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
- Opthalmic Probiotic + Oral Probiotic (Type: EXPERIMENTAL): 1 active drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
- Oral Probiotic (Type: EXPERIMENTAL): 1 placebo drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Dexamethasone and Ibuprofen on Pain Prevention and Control Following Surgical Implant Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent for the described procedure~* Surgical placement of a single endosteal implant~* Age of at least 18 years~Exclusion Criteria:~* The need for bone grafting or sinus lift for implant placement~* Pregnant and lactating women~* Metabolic disorders~* Immunocompromised status~* Hemophilia or bleeding disorders~* Drug or alcohol abuse~* Treatment with steroids in the previous 6 months~* History of radiation therapy in the head and neck~* Psychiatric disorders~* Inability to understand the procedure described in the questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1- Received Ibuprofen (N=44) (Type: ACTIVE_COMPARATOR): None
- Group 2- Received Dexamethasone (N=44) (Type: ACTIVE_COMPARATOR): None
- Group 3 - Received Placebo (N=44) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids~* Further criteria as defined in the study protocol~Exclusion Criteria:~* Use of oral corticosteroids within past 3 months~* Hospitalization for asthma exacerbation within past 6 months~* Uncontrolled asthma~* Contraindication to any study test or procedure~* Further criteria as defined in the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Atopic Dermatitis (AD): Have been diagnosed with AD for at least 3 months; Have an Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate); Have AD covering 5% to 20% (inclusive) of BSA.~* Plaque psoriasis: Have been diagnosed with plaque psoriasis (psoriasis vulgaris) for at least 6 months; Have a Physician Global Assessment (PGA) score of 2 (mild), or 3 (moderate); Having plaque psoriasis covering 5% to 15% (inclusive) of BSA.~Exclusion Criteria:~* Presence of skin comorbidities that would interfere with study assessment or response to treatment.~* Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- atopic dermatitis - PF-07038124 ointment (Type: EXPERIMENTAL): None
- atopic dermatitis - vehicle ointment (Type: PLACEBO_COMPARATOR): None
- plaque psoriasis - PF-07038124 ointment (Type: EXPERIMENTAL): None
- plaque psoriasis - vehicle ointment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes, but otherwise healthy~* HbA1c between 6.6% and 9.5%, inclusive.~* Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.~* Treated with a stable dose of metformin for at least 2 months prior to screening.~Exclusion Criteria:~* Patients previously in a study using exenatide.~* Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening).~* Treated with insulin within 3 months of screening.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Arm (Type: EXPERIMENTAL): Exenatide and Metformin
- Insulin Glargine Arm (Type: ACTIVE_COMPARATOR): Insulin Glargine and Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 1 and 12 years~* otorrhea for more than 3 months~Exclusion Criteria:~* cholesteatoma~* known immune deficiency other than IgA or IgG2~* Down's syndrome~* craniofacial anomalies~* cystic fibrosis~* immotile cilia syndrome~* allergy to sulfamethoxazole-trimethoprim~* continuous use of sulfamethoxazole-trimethoprim for more than six weeks in the past six months

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- Sulfamethoxazole-trimethoprim (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing SSRF at Denver Health Medical Center~Exclusion Criteria:~* Allergy or hypersensitivity to bupivacaine~* Pregnancy~* Incarceration~* Age \< 18 years~* Indwelling continuous thoracic epidural analgesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bupivacaine indwelling catheter (Type: ACTIVE_COMPARATOR): Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
- Liposomal bupivacaine injection (Type: ACTIVE_COMPARATOR): A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants 18 to 80 years of age~* Participants should be qualified for inclusion based upon estimated CrCl ranges for normal renal function group and mild, moderate, and severe renal impairment groups~Exclusion Criteria:~* Participants with acute renal disease and/or history of renal transplant~* Urinary incontinence without catheterization~* Participants requiring hemodialysis~* Participants with LDL-C \<60 mg/deciliter (dL) (or less than 1.55 millimoles/liter \[mmol/L\])~* Participants with Amyloid Kidney (if known by pathology)~* Participants with any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephritic~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Inclisiran (normal renal function) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
- Inclisiran (mild renal impairment) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
- Inclisiran (moderate renal impairment) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
- Inclisiran (severe renal impairment) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* 18 to 45 years of age~* Body mass index (BMI) between 18 and 30 kg/m2~Exclusion Criteria:~* Conspicuous findings (medical history, screening)~* History of relevant diseases (internal organs, central nervous system or other organs)~* Medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor~* Febrile illness within 1 week before the start of the study~* History of severe allergies, non-allergic drug reactions, or multiple drug allergies~* Hypersensitivity to the investigational drug, the control agent and/or to inactive constituents~* Known coagulation disorders, known disorders with increased bleeding risk, known sensitivity to common causes of bleeding

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg (Type: EXPERIMENTAL): Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
- Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg (Type: EXPERIMENTAL): Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks~* HbA1c greater than or equal to 7.0% and less than 10.0%~* BMI less than 35 kg/m2~Exclusion Criteria:~* Treatment with insulin within the last 12 weeks~* Treatment with any drug that could interfere with the glucose level~* Any serious medical condition~* Females who are pregnant, have intention of becoming pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.6 mg + SU (Type: EXPERIMENTAL): Liraglutide 0.6 mg + sulphonylurea
- 0.9 mg + SU (Type: EXPERIMENTAL): Liraglutide 0.9 mg + sulphonylurea
- SU Mono - 1 (Type: PLACEBO_COMPARATOR): Liraglutide placebo 0.6 mg + sulphonylurea
- SU Mono - 2 (Type: PLACEBO_COMPARATOR): Liraglutide placebo 0.9 mg + sulphonylurea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Saizen in Intra-uterine Growth Retardation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previous inclusion, good compliance and normal completion of GF4001 or GF6283 in the treatment of growth failure in children born with serious IUGR (3-year continuous r-hGH treatment in GF4001 or 2-year continuous or intermittent r-hGH treatment in GF6283).~* Increase in height greater than 0.5 standard deviation (SD) during the first 2 years of r-hGH treatment in GF4001 or after 2 years of continuous or intermittent r-hGH treatment in GF6283.~* A written Informed Consent at the beginning of the pre-study visit must be obtained from the parent(s)/legal guardian(s), with the understanding that consent may be withdrawn by the subject or parents at any time without prejudice to their future medical care. Children able to understand the trial should personally sign and date the written informed consent, too.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known multiple malformation syndrome with severe psychomotor retardation and/or body hemihypertrophy.~* Severe psychomotor retardation.~* Severe congenital malformations.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saizen® (Continuous or intermittent treatment) (Type: EXPERIMENTAL): None
- Saizen® (Observed and then continuous or no treatment) (Type: EXPERIMENTAL): None
- Observation only (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete